

SCOLIOSIS SUPPORT AND RESEARCH
ANNUAL REPORT & ACCOUNTS
31ST MARCH 2025

Registered Charity Number 1181463

EDMUND CARR LLP
Chartered Accountants
146 New London Road
Chelmsford
Essex
CM2 0AW

SCOLIOSIS SUPPORT AND RESEARCH

YEAR ENDED 31 MARCH 2025

CONTENTS

Reference & Admin Details	1
Report of the Trustees	2
Independent examiner's report	5
Statement of Financial Activities (incorporating the income and expenditure account)	6
Balance Sheet	7
Cashflow Statement	8
Notes to the financial statements	10

SCOLIOSIS SUPPORT AND RESEARCH

REFERENCE AND ADMINISTRATIVE DETAILS

YEAR ENDED 31 MARCH 2025

Registered Charity Name	Scoliosis Support and Research formerly Scoliosis Association UK (SAUK)
Charity Number	1181463
Registered Office	Ground Floor 329 Latimer Road London W10 6RA
Trustees	Mr I Nelson (Chair) Mrs H Gale (Appointed December 2024) Dr N Jones Mr J Leong Mr C Nnadi Dr M Noordeen Mr T Tsirikos (Resigned December 2024) Ms R Weil Mr J Zorab
Patron	HRH Princess Eugenie
Chief Executive	Lesley McGinty
Independent Examiner	Alex Stone FCCA Edmund Carr LLP Chartered Accountants 146 New London Road Chelmsford Essex CM2 0AW
Bankers	CAF Bank 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4JQ

SCOLIOSIS SUPPORT AND RESEARCH

TRUSTEES' ANNUAL REPORT

YEAR ENDED 31 MARCH 2025

The Trustees have pleasure in presenting their report and the unaudited financial statements of the charity for the year ended 31 March 2025.

Annual Report from the Chair, 2024-25

Having legally completed the merger of Scoliosis Association UK and British Scoliosis Research Foundation (BSRF) in January 2023, January 2024 saw the official launch of our new name, Scoliosis Support and Research, with associated rebranding to reflect our ethos and “personality”. This relaunch was very well received, with very positive feedback. We completely rebuilt the website with much more information. This is still very much work in progress, with new functionality being added.

The objects of the charity, revised post merger are, for the public benefit, to preserve and protect the physical and mental health of persons with the spinal condition known as scoliosis and other spinal conditions, particularly but not exclusively by:

- (i) providing advice, support and information to people affected by scoliosis and other spinal conditions, their families and friends;
- (ii) raising awareness of scoliosis and other spinal conditions among health professionals and the general public;
- (iii) making available to patients and their families and friends the experience of others with scoliosis and other spinal conditions;
- (iv) raising awareness about the prevalence and effects of scoliosis and other spinal conditions;
- (v) promoting research into scoliosis and other spinal conditions and more particularly into their causes and into the chest and heart consequences thereof;
- (vi) holding the international Philip Zorab Symposium, a unique international scoliosis meeting, at a frequency to be determined by the trustees and the Zorab Committee chair.

We continue to support those affected by scoliosis through our Helpline – by telephone and email – as well as providing online counselling groups and a “safe space” on our Facebook group.

We have expanded the scope of our community (membership) to enable more people to access our Hill Pedder Minns Welfare fund and twice yearly Backbone Magazine.

During this year, we started organising Patient Events again. We organise events of up to 100 people in locations across the UK to discuss the issues faced by families and individuals affected by scoliosis. These provide the opportunity to hear from scoliosis specialists and treatment experts, and get answers to your questions. They are also a great opportunity for people to meet each other and share stories and information about their experiences with scoliosis.

We support research by collaborating with researchers and making our members aware of the research and inviting them to participate. We have continued to offer the Charles Manning Award, which was a BSRF award arising from a legacy by Mr. Charles Manning, FRCS, to help early career researchers attend conferences to present their work. We awarded a total of £1,150 this financial year. Our patient events and greater social media presence have offered far more opportunity for patients to become involved with research, as specified in our Priority Setting Partnership.

SCOLIOSIS SUPPORT AND RESEARCH

TRUSTEES' ANNUAL REPORT (*continued*)

YEAR ENDED 31 MARCH 2025

The internationally renowned Zorab Symposium, which was historically organised by BSRF, was held on 19 and 20 June 2025.

Structure, governance, and management

Scoliosis Support and Research (SSR) - formerly Scoliosis Association UK - was incorporated on January 7th, 2019, as a charitable incorporated organisation (CIO). The CIO is entered in the Central Register of Charities by the Charity Commissioners for England and Wales with registration number 1181463.

SSR is governed by a board of Trustees, consisting of a combination of spinal surgeons, general practitioners, scientists, and lay members. The office staff is composed of a Chief Executive, supported by a Community Engagement Manager and a Fundraising and Communications Manager.

The Board of Trustees meets four times a year and the Chief Executive reports formally to the Board at these meetings. New Trustees are generally selected from contacts with knowledge of scoliosis and related issues. Following a Strategy day in October 2024 we have plans to diversify trustee expertise through subsequent replacements.

The Trustees confirm that they have had due regard to guidance published by the Charity Commission on public benefit. SSR's aims are wholly directed at delivering public benefit.

The trustees have considered the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate these risks. Key areas of focus include, financial sustainability, data protection, and reputational risk.

The trustees recognise the importance of risk management and are in the process of developing a formal risk register. Key risks are discussed regularly at board meetings and mitigation strategies are considered as part of ongoing governance.

During the reporting period, there were no related party transactions. No trustee or member of staff received any remuneration or reimbursement for services provided to the charity, nor did any have a financial interest in any contract or grant provided by the charity.

The Trustees of SSR are listed on page 1. HRH Princess Eugenie is SSR's Royal Patron

Dr Stephanie Clark, PhD, co-founder of Scoliosis Association UK was appointed as a Patron on standing down from the Board back in December 2023.

The staff team during 2024 -25 consisted of Mrs Lesley McGinty, who has been in post as Chief Executive since April 2021; Ellie Wilson, Fundraising and Communications Officer, November 2023 to December 2024; James Alculmbre as Community Engagement Manager from June 2024 and Will Thommes who rejoined us as Fundraising and Communications Manager in January 2025. All employees are based at SSR's premises at Ground Floor 329 Latimer Road, London W10 6RA.

SCOLIOSIS SUPPORT AND RESEARCH
TRUSTEES' ANNUAL REPORT (*continued*)
YEAR ENDED 31 MARCH 2025

Finance

Unrestricted income, made up of donations, legacies, and fundraised income including Gift Aid was £325,631 compared with £202,176 in the previous year. Notably, Community Fundraising increased from £62,143 to £108,824 thanks in no small part to a large, very engaged Marathon team. Our membership subscriptions stayed much the same as in the previous year. We spent £302,756 in the current year compared with £277,359 in the previous year largely due to the costs of the rebrand, a fundraising consultant and legal fees for a research agreement. Legacies brought in £120,231 with notification of a significant legacy (over £200k) to be received in the next financial year. We are developing new projects and ways to support people with scoliosis, with the benefit of the increased funds.

During the year we paid out a total of £43,986 in respect of research grants awarded in the current and prior years; £10,269 in respect of support grants, defrayed by a very generous donation of £3,000, and as mentioned above, £1,150 for research travel grants via the Charles Manning Award. We received continued support from the Sir James Reckitt Charity (support) and the Robert Luff Foundation (research).

SSR had total funds at the year end of £1,261,146 of which £617,922 were unrestricted, £469,808 designated and £173,416 restricted. Our reserves policy is to maintain a minimum of £100,000 of unrestricted funds. Our unrestricted funds were significantly higher than this at the year end due to the transfer of assets at point of merger and the receipt of a significant legacy in 2023. Funds will be used to scope and sponsor a research project of £100,000 plus, and further develop patient support through regional meetings and talking therapy support.

It was agreed by the Board that £1million was to be invested and after the required due diligence and security was undertaken, this was completed in July 2024, with our investment being managed by Rathbones.

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

Approved by the Trustees on 3 November 2025 and signed on their behalf by:

Ian Nelson
.....

Ian Nelson
Chair of the Trustees

SCOLIOSIS SUPPORT AND RESEARCH
INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES
YEAR ENDED 31 MARCH 2025

I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2025 which are set out on pages 6 to 16.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the charity's accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Certified Accountants, which is one of the listed bodies.

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Alex Stone

.....
Alex Stone FCCA

Edmund Carr LLP
146 New London Road
Chelmsford
CM2 0AW

3 November 2025

SCOLIOSIS SUPPORT AND RESEARCH
STATEMENT OF FINANCIAL ACTIVITIES
YEAR ENDED 31 MARCH 2025

	Note	Unrestricted Funds 2025 £	Restricted Funds 2025 £	Total Funds 2025 £	Total Funds 2024 £
Income from:					
Donations and legacies	2	288,587	25,000	313,587	265,579
Other trading activities	3	2,627	-	2,627	1,571
Investments	4	21,480	-	21,480	23,545
Charitable activities	5	12,937	-	12,937	15,095
Total Income		325,631	25,000	350,631	305,790
Expenditure on:					
Raising funds		8,022	-	8,022	7,386
Charitable activities	6	293,584	1,150	294,734	269,973
Total Expenditure		301,606	1,150	302,756	277,359
Net income/(expenditure)		24,025	23,850	47,875	28,431
Net gains/(losses) on investments	10	(32,850)	-	(32,850)	-
Transfers between funds		-	-	-	-
Net Movement in Funds		(8,825)	23,850	15,025	28,431
Reconciliation of Funds					
Total funds brought forward		1,096,555	149,566	1,246,121	1,217,690
Total Funds Carried Forward		£1,087,730	£173,416	£1,261,146	£1,246,121

All of the above amounts relate to continuing activities.

The notes on pages 9 to 16 form part of these financial statements.

SCOLIOSIS SUPPORT AND RESEARCH

BALANCE SHEET

AS AT 31 MARCH 2025

	Note	2025	2024
		£	£
Fixed Assets			
Tangible fixed assets	10	444	888
Investments	11	<u>1,117,160</u>	<u>-</u>
		1,117,604	888
Current Assets			
Debtors	12	37,934	66,480
Cash at bank and in hand		<u>174,370</u>	<u>1,255,791</u>
		212,304	1,322,271
Creditors: Amounts falling due within one year	13	<u>(68,762)</u>	<u>(77,038)</u>
Net Current Assets		<u>143,542</u>	<u>1,245,233</u>
Net Assets		<u><u>1,261,146</u></u>	<u><u>1,246,121</u></u>
The funds of the charity:			
Unrestricted Funds	15	617,922	610,678
Designated Funds		<u>469,808</u>	<u>485,877</u>
Total Unrestricted Funds		1,087,730	1,096,555
Restricted Funds	16	<u>173,416</u>	<u>149,566</u>
Total Charity Funds		<u><u>1,261,146</u></u>	<u><u>1,246,121</u></u>

These financial statements were approved by the Trustees on 3 November 2025 and are signed on their behalf by:

Ian Nelson

IAN NELSON (CHAIR OF THE TRUSTEES)

The notes on pages 9 to 16 form part of these financial statements.

SCOLIOSIS SUPPORT AND RESEARCH
CASHFLOW STATEMENT
YEAR ENDED 31 MARCH 2025

	Note	2025	2024
Cash flows from operating activities:			
Net movement in funds		15,025	28,431
<i>Adjustments for:</i>			
Depreciation charges	10	444	444
Revaluation of Investment	11	32,850	-
Investment income	4	(21,480)	(23,545)
Decrease / (increase) in debtors	12	28,546	(60,943)
Increase / (decrease) in creditors	14	(8,276)	(74,784)
Cash provided by / (used in) operating activities		<u>47,109</u>	<u>(130,397)</u>
Cash flows from investing activities:			
Investment income	4	21,480	23,545
Purchase of Investment	11	(1,150,010)	-
Cash provided by investing activities		<u>(1,128,530)</u>	<u>23,545</u>
Increase / (decrease) in cash and cash equivalents in the year		(1,081,421)	(106,852)
Cash and cash equivalents at start of year		<u>1,255,791</u>	<u>1,362,643</u>
Cash and cash equivalents at end of year		<u><u>174,370</u></u>	<u><u>1,255,791</u></u>

The notes on pages 9 to 16 form part of these financial statements.

SCOLIOSIS SUPPORT AND RESEARCH
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 MARCH 2025

1) ACCOUNTING POLICIES

General information and basis of preparation

Scoliosis Support and Research is a Charitable Incorporated Organisation, registered in England and Wales (charity no: 1181463).

The charity constitutes a public benefit entity as defined by FRS102.

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) issued in October 2019, the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Charities Act 2011 and UK Generally Accepted Accounting Practice.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair view'. This departure has involved following the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

The financial statements are prepared on a going concern basis under the historical cost convention modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest £1.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

Income recognition

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income can be measured reliably.

Expenditure recognition

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to the category.

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Governance costs are those incurred in connection with the administration of the charity and compliance with constitutional and statutory requirements.

Irrecoverable VAT is charged as an expense against the activity for which the expenditure arose.

SCOLIOSIS SUPPORT AND RESEARCH
NOTES TO THE FINANCIAL STATEMENTS
YEAR ENDED 31 MARCH 2025

1) ACCOUNTING POLICIES (continued)

Taxation

The charity is exempt from taxation in respect of income or capital gains to the extent that such income or gains are applied exclusively to charitable purposes.

Fixed assets

The charity's policy is to capitalise fixed assets over £1,000. Expenditure below this threshold is recognised as expenditure in the year in which it occurs.

Depreciation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Equipment	25% straight line

Investments

Investments are stated at market value. Realised gains and losses on disposals and unrealised gains or losses when the investments are revalued at the period end are reflected in the Statement of Financial Activities.

Stocks

No value is placed on stocks of stationery or advertising materials held by the charity.

Debtors and creditors receivable /payable within one year

Debtors and creditors receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and at bank.

Fund Accounting

Funds held by the charity are either:

Unrestricted general funds - these are funds that can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds - these are funds that can only be used for particular restricted purposes within the objects of the charity.

Designated funds - these are funds that have been set aside by the trustees for particular purposes.

SCOLIOSIS SUPPORT AND RESEARCH

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MARCH 2025

2) DONATIONS & LEGACIES

	Unrestricted funds £	Restricted funds £	Total funds 2025 £	Total funds 2024 £
Donations	158,413	-	158,413	109,686
Legacies	120,231	-	120,231	42,887
Gift aid	6,943	-	6,943	6,392
Grants	3,000	25,000	28,000	106,614
	<u>288,587</u>	<u>25,000</u>	<u>313,587</u>	<u>265,579</u>

Legacies notified to the charity during the year which did not meet income recognition criteria at the year end have an estimated value of £275,000 (2024 - nil).

3) OTHER TRADING ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds 2025 £	Total funds 2024 £
Website sales	<u>2,627</u>	-	<u>2,627</u>	<u>1,571</u>

4) INVESTMENTS

	Unrestricted funds £	Restricted funds £	Total funds 2025 £	Total funds 2024 £
Bank interest receivable	10,565	-	10,565	23,545
Investment Income	10,915	-	10,915	
	<u>21,480</u>	<u>-</u>	<u>21,480</u>	<u>23,545</u>

5) INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds 2025 £	Total funds 2024 £
Subscriptions	<u>12,937</u>	-	<u>12,937</u>	<u>15,095</u>

SCOLIOSIS SUPPORT AND RESEARCH

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MARCH 2025

6) EXPENDITURE ON CHARITABLE ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds 2025 £	Total funds 2024 £
Awards	6,069	1,150	7,219	4,539
Provision of Therapy	4,200	-	4,200	-
Research Grants	10,000	-	10,000	3,462
Events	12,822	-	12,822	3,643
Staff costs	136,176	-	136,176	154,126
Website and magazine costs	18,135	-	18,135	14,485
Support costs (Note 7)	98,522	-	98,522	64,418
Governance costs (Note 8)	7,660	-	7,660	25,300
	<u>293,584</u>	<u>1,150</u>	<u>294,734</u>	<u>269,973</u>

7) SUPPORT COSTS

	Unrestricted funds £	Restricted funds £	Total funds 2025 £	Total funds 2024 £
Office costs	90,251	-	90,251	59,587
Meetings, travel & subsistence	3,938	-	3,938	2,221
Bank Charges	4,333	-	4,333	2,610
	<u>98,522</u>	<u>-</u>	<u>98,522</u>	<u>64,418</u>

8) GOVERNANCE COSTS

	Unrestricted funds £	Restricted funds £	Total funds 2025 £	Total funds 2024 £
Fees payable to independent examiner	4,500	-	4,500	5,100
Other professional fees	3,160	-	3,160	20,200
	<u>7,660</u>	<u>-</u>	<u>7,660</u>	<u>25,300</u>

9) STAFF COSTS AND EMOLUMENTS

	2025 £	2024 £
Salaries and wages	125,417	143,717
Social security costs	8,751	8,389
Employer pension costs	2,008	2,020
	<u>136,176</u>	<u>154,126</u>

Average number of paid staff on a head count basis for the year was 3 (2024 - 7)

Remuneration benefits of key management personnel of the charity total £67,492 (2024: £60,518).

SCOLIOSIS SUPPORT AND RESEARCH
NOTES TO THE FINANCIAL STATEMENTS (continued)
YEAR ENDED 31 MARCH 2025

10) TANGIBLE FIXED ASSETS

	Equipment £	Total £
COST		
As at 1 April 2024	1,776	1,776
Additions	-	-
At 31 March 2025	<u>1,776</u>	<u>1,776</u>
DEPRECIATION		
As at 1 April 2024	888	888
Charge for the period	444	444
At 31 March 2024	<u>1,332</u>	<u>1,332</u>
NET BOOK VALUE		
At 31 March 2025	<u>444</u>	<u>444</u>
At 31 March 2024	<u>888</u>	<u>888</u>

11) INVESTMENTS

	2025 £	2024 £
Market value as at 1 April 2024	-	-
Additions at cost	1,150,010	-
Net loss on revaluation	(32,850)	-
Market value as at 31 March 2025	<u>1,117,160</u>	<u>-</u>

All investments are managed by Rathbones Investment Management.

12) DEBTORS

	2025 £	2024 £
Other debtors	6,800	6,800
Prepayments and accrued income	31,134	59,680
	<u>37,934</u>	<u>66,480</u>

SCOLIOSIS SUPPORT AND RESEARCH

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 MARCH 2025

13) CREDITORS: Amounts falling due within one year

	2025	2024
	£	£
Creditors	4,772	4,292
Research Grants Payable	59,704	69,136
Accruals	4,286	3,610
	<u>68,762</u>	<u>77,038</u>

14) COMMITMENTS UNDER OPERATING LEASES

Total rental payments due under operating leases are as follows:

	2025	2024
	£	£
Within 1 year	4,121	24,727
Within 2 to 5 years	-	4,121
	<u>4,121</u>	<u>28,848</u>

15) UNRESTRICTED FUNDS

	Balance at 1 Apr 2024	Income	Expenditure	Gains/ (losses)	Balance at 31 Mar 2025
	£	£	£	£	£
General funds	610,678	322,631	(282,537)	(32,850)	617,922
<i>Designated funds:</i>					-
a) Ailee Harrison Fund	4,675	-	(350)	-	4,325
b) Hill, Pedder, Minns Fund	28,226	-	(5,719)	-	22,507
c) BSRF funds	452,976	-	(10,000)	-	442,976
d) Counselling Support	-	3,000	(3,000)	-	-
	<u>1,096,555</u>	<u>325,631</u>	<u>(301,606)</u>	<u>(32,850)</u>	<u>1,087,730</u>

- The Ailee Harrison Fund arose from a legacy and is used to provide financial prizes for art projects.
- The Hill, Pedder, Minns Fund arose from 3 legacies and is used to provide grants to members of up to £500 for equipment relating to their condition.
- Funds transferred from BSRF have been designated for research purposes by the Trustees.
- Donations to aid with counselling support.

SCOLIOSIS SUPPORT AND RESEARCH
NOTES TO THE FINANCIAL STATEMENTS (continued)
YEAR ENDED 31 MARCH 2025

16) RESTRICTED FUNDS

	Balance at 1 Apr 2024	Income	Expenditure	Investment gains/ (losses)	Balance at 31 Mar 2025
	£	£	£	£	£
a) ARISE	15,098	-	(1,150)	-	13,948
b) BEIS fund (BSRF)	30,854	-	-	-	30,854
c) Research funds	103,614	25,000	-	-	128,614
	<u>149,566</u>	<u>25,000</u>	<u>(1,150)</u>	<u>-</u>	<u>173,416</u>

- a) ARISE fund provides travel grants of up to £500 to young researchers (the Charles Manning Award).
b) Funds awarded by the BEIS 'Early Career Researchers Fund' to BSRF towards research projects supported by the charity were transferred to SSR following the merger.
c) Grants received from Robert Luff Foundation and the Medical Research Council to fund research projects.

Current Year	Fixed assets	Net current assets	Total
	£	£	£
Unrestricted funds			
General	474,380	143,542	617,922
Designated funds	469,808	-	469,808
Restricted funds	173,416	-	173,416
Total funds	<u>1,117,604</u>	<u>143,542</u>	<u>1,261,146</u>

Prior year	Fixed assets	Net current assets	Total
	£	£	£
Unrestricted funds			
General	888	609,790	610,678
Designated funds	-	485,877	485,877
Restricted funds	-	149,566	149,566
Total funds	<u>888</u>	<u>1,245,233</u>	<u>1,246,121</u>

18) RELATED PARTY TRANSACTIONS

There were no related party transactions during the year (2024 - nil).
Trustees do not receive any remuneration or fees. One trustee was reimbursed for expenses totalling £325 in respect of travel and subsistence (2024 - 3 trustees were reimbursed £1,037).

SCOLIOSIS SUPPORT AND RESEARCH
NOTES TO THE FINANCIAL STATEMENTS (continued)
YEAR ENDED 31 MARCH 2025

19) UNRESTRICTED FUNDS - PRIOR YEAR

	Balance at 1 Apr 2023 £	Income £	Expenditure £	Balance at 31 Mar 2024 £
General funds	671,990	202,176	(263,488)	610,678
<i>Designated funds:</i>				
a) Ailee Harrison Fund	4,675	-	(3,639)	1,036
b) Hill, Pedder, Minns Fund	31,865	-	(9,332)	22,533
c) BSRF funds	462,308	-	-	462,308
	<u>1,170,838</u>	<u>202,176</u>	<u>(276,459)</u>	<u>1,096,555</u>

- a) The Ailee Harrison Fund arose from a legacy and is used to provide financial prizes for art projects.
- b) The Hill, Pedder, Minns Fund arose from 3 legacies and is used to provide grants to members of up to £500 for equipment relating to their condition.
- c) Funds transferred from BSRF have been designated for research purposes by the Trustees.

20) RESTRICTED FUNDS - PRIOR YEAR

	Balance at 1 Apr 2023 £	Income £	Expenditure £	Balance at 31 Mar 2024 £
a) ARISE	15,998	-	(900)	15,098
b) BEIS fund (BSRF)	30,854	-		30,854
c) Research Funds	-	103,614	-	103,614
	<u>46,852</u>	<u>103,614</u>	<u>(900)</u>	<u>149,566</u>

- a) ARISE fund provides travel grants of up to £500 to young researchers (the Charles Manning Award).
- b) Funds awarded by the BEIS 'Early Career Researchers Fund' to BSRF towards research projects supported by the charity were transferred to SSR following the merger.
- c) Grants received from Robert Luff Foundation and the Medical Research Council to fund research projects.